Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELAMI: Belantamab Mafodotin and Mezigdomide in Relapsed Multiple Myeloma
NCT07612787Phase 2Not yet recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Dec 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of belantamab mafodotin and mezigdomide in multiple myeloma (MM), sponsored by CHU Saint-Etienne. Primary endpoint: Progression Free Survival at 5 years. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
belantamab mafodotinmezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07612787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612787.